Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content. If you have any issues relating to the topics here, please call the MS-UK Helpline on 0800 7830 518.


 

Scientists are investigating a way to use temporary tattoos that deliver nanoparticles to treat autoimmune diseases like multiple sclerosis.

“Placed just under the skin, the carbon-based...

The U.S. Department of Health and Human Services (HHS) recently announced policy changes designed to make information about clinical trials of investigational drugs, biologics and products more...

A drug currently being developed for people living with multiple sclerosis has shown promising results to stop the progression of the disease in mice. Known as Laquinimod, it is being tested in...

Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) a Novartis report found that siponimod (BAF312) reduced the risk of disability progression in a Phase...

Lemtrada (alemtuzumab) as a first treatment option for relapsing multiple sclerosis reduced relapse rates and disability progression throughout a study period of six years — although most patients...

A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis drug Tecfidera®. The drug is the most widely prescribed...

University of Maryland researchers have manipulated lymph nodes to “switch off” autoimmune attacks in diseases like multiple sclerosis while preserving healthy immune function. The treatment,...

Novartis recently announced positive results from the ACROSS study, which is assessing the clinical effect of Gilenya (fingolimod) in 10-year disability outcomes in people with relapsing-remitting...

A recent phase IV study showed that after one year, the majority of multiple sclerosis patients taking oral Gilenya (fingolimod) therapy stuck with their treatment, while a large proportion of...

A recent study showed that the clinical benefits offered by Ampyra (fampridine) in improving mobility among multiple sclerosis patients has clinical significance.

The results were shown in...

Pages